Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia
Eytan Stein, MD, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).
Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).
Stein says all patients with AML have a multitude of mutations that are causing their disease, and that targeting single mutations such as FLK3 and IDH may not be enough to make an impact. He adds that combining agents that, for example, target both of those mutations could very well be the future of the treatment paradigm.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
